
via Phys.org
Engineering cellular biology, minus the actual cell, is a growing area of interest in biotechnology and synthetic biology. It’s known as cell-free protein synthesis, or CFPS, and it has potential to provide sustainable ways to make chemicals, medicines and biomaterials.
Unfortunately, a long-standing gap in cell-free systems is the ability to manufacture glycosylated proteins – proteins with a carbohydrate attachment. Glycosylation is crucial for a wide range of important biological processes, and the ability to understand and control this mechanism is vital for disease treatment and prevention.
Matthew DeLisa, the William L. Lewis Professor of Engineering in the Smith School of Chemical and Biomolecular Engineering, and Michael Jewett, associate professor of chemical and biological engineering at Northwestern University, have teamed up on a novel approach that bridges this gap. Their system, the first of its kind, capitalizes on the recent advances in CFPS while adding the crucial glycosylation component in a simplified, “one-pot” reaction. In the future, their cell-free glycoprotein synthesis system could be freeze-dried and reactivated for point-of-use protein synthesis by simply adding water.
DeLisa and Jewett are co-senior authors of “Single-pot Glycoprotein Biosynthesis Using a Cell-Free Transcription-Translation System Enriched with Glycosylation Machinery,” published July 12 in Nature Communications.
Thapakorn Jaroentomeechai, Ph.D. student in the DeLisa Research Group, and Jessica Stark ’12, Ph.D. student in the Jewett group, are co-first authors.
“If you really want to have a useful, portable and deployable vaccine or therapeutic protein technology that’s cell free, you have to figure out the carbohydrate attachment,” DeLisa said. “That’s, in essence, what we’ve done in a very powerful way.”
This work could impact development of decentralized manufacturing strategies. Rapid access to protein-based medicines in remote settings could change lives; new biomanufacturing paradigms suitable for use in low-resource settings might promote better access to costly drugs through local, small-batch production.
DeLisa has done a great deal of research on the molecular mechanisms underlying protein biogenesis in the complex environment of a living cell, such as Escherichia coli (E. coli). While his lab has made some notable breakthroughs, the limitations of this area, he said, are the cell walls themselves.
Jewett’s lab at Northwestern has invested much of its research efforts into cell-free synthetic biology, which leverages nature’s most elegant biomachinery outside the confines of the cell, so a collaboration was a natural extension of both labs’ work.
“In bacterial cell engineering, you’re constantly in a tug of war,” Jewett said. “You’re introducing a mechanism or capability that’s of interest to you as a scientist, but what the cell is trying to do for itself is grow and survive.”
For their new method, the team prepared cell extracts from an optimized laboratory strain of E. coli, CLM24, that were selectively enriched with key glycosylation components. The resulting extracts enabled a simplified reaction scheme, which the team has dubbed cell-free glycoprotein synthesis (CFGpS).
“A major advance of this work is that our cell-free extracts contain all of the molecular machinery for protein synthesis and protein glycosylation,” Stark said. “What that means is you only need to add DNA instructions for your protein of interest to make a glycoprotein in CFGpS. This is a drastic simplification from cell-based methods and allows us to make sophisticated glycoprotein molecules in less than a day.”
And the CFGpS method is highly modular, allowing for the use of distinct and diverse extracts to be mixed for the production of a variety of glycoproteins.
“Because we chose E. coli, which lacks its own glycosylation machinery, to build our CFGpS platform, it gave us a blank slate for bottom-up engineering of any desired glycosylation system,” Jaroentomeechai said. “This gives us the unique ability to control carbohydrate structures and purities of the glycoproteins at levels that are not currently achievable in other cell-based expression systems.”
Even in developed countries like the U.S., the move toward personalized medicine makes this type of on-demand drug production protocol attractive. “You could use a test tube instead of a 50,000-liter bioreactor to make your product, which opens the door to a personalized biomanufacturing paradigm where each patient can receive a unique protein medicine tailored to their physiology,” he said.
Learn more: Bioengineers create pathway to personalized medicine
The Latest on: Personalized biomanufacturing
via Google News
The Latest on: Personalized biomanufacturing
- Cytiva named as founding member of Watertown biomanufacturing facilityon January 15, 2021 at 2:10 pm
Marlborough’s Cytiva, the rebranded GE Healthcare Life Sciences, has been named as a founding member of a forthcoming 40,000 square-foot manufacturing and innovation center at the The Arsenal on ...
- Precision Medicine Group Significantly Expands Cell And Gene Therapy Expertise With Acquisition Of Project Farmaon January 14, 2021 at 1:36 am
Precision Medicine Group ("PMG") announced today it has acquired Project Farma, a patient-focused bioengineering services firm that supports life science innovators in the manufacturing and ...
- Sustainability and the Synthetic Biology Revolutionon January 9, 2021 at 6:16 am
In theory, this would be a significant healthcare advancement; in practice, we must find more efficient ways to develop this new generation of personalized therapies—we need to be smarter.
- MilliporeSigma Acquires AmpTec to Expand mRNA Capabilities for Vaccines, Treatments and Diagnosticson January 7, 2021 at 1:19 am
Adds to MilliporeSigma’s lipid manufacturing expertise, providing an integrated offering across mRNA value chain - AmpTec’s differentiated polymerase chain reaction (PCR)-based technology has shown to ...
- Worldwide Industry for Microbial Contract Biomanufacturing to 2030 - COVID-19 is Likely to Create Significant Business Opportunitieson December 22, 2020 at 3:30 am
For more information about this report visit https://www.researchandmarkets.com/r/v3ecei ...
- Worldwide Industry for Microbial Contract Biomanufacturing to 2030 - COVID-19 is Likely to Create Significant Business Opportunitieson December 22, 2020 at 3:10 am
© 2021 Insider Inc. and finanzen.net GmbH (Imprint). All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Service and ...
- People to meet in 2021: Mike O’Brienon December 20, 2020 at 4:01 pm
Behind O’Brien and with the help of Matthew Zicaro, a vice president with life science experience, Galaxy is making a huge bet on Worcester’s future as a place for biomanufacturing.
- Hollow Fiber Membrane Market is Slated to Reach $16 Billion by 2026, Says Global Market Insights Inc.on December 14, 2020 at 4:45 am
Expansion in the biomanufacturing industry ... Offering syndicated and custom research reports, growth consulting, and business intelligence services, Global Market Insights, Inc. aims to help ...
- Insights on the Microbial Contract Biomanufacturing Global Market to 2030 - Featuring AGC Biologics, Aldevron and BioVectra Among Otherson December 10, 2020 at 4:11 am
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] ...
via Bing News